ICER #WeeklyView: The most important ICER stories of 2024 https://conta.cc/41JvIrR
Institute for Clinical and Economic Review (ICER)
Hospitals and Health Care
Working towards Fair Pricing, Fair Access, and Future Innovation
About us
The Institute for Clinical and Economic Review (ICER) is an independent, non-profit research institute that conducts evidence-based reviews of health care interventions, including prescription drugs, other treatments, and diagnostic tests. In collaboration with patients, clinical experts, and other key stakeholders, ICER analyzes the available evidence on the benefits and risks of these interventions to measure their value and suggest fair prices. ICER also regularly reports on the barriers to care for patients and recommends solutions to ensure fair access to prescription drugs. For more information about ICER, please visit www.icer.org.
- Website
-
http://www.icer.org
External link for Institute for Clinical and Economic Review (ICER)
- Industry
- Hospitals and Health Care
- Company size
- 11-50 employees
- Headquarters
- CIity
- Type
- Nonprofit
- Founded
- 2006
- Specialties
- Comparative effectiveness research and Health policy
Locations
-
Primary
Get directions
CIity, US
Employees at Institute for Clinical and Economic Review (ICER)
Updates
-
Institute for Clinical and Economic Review Publishes Fourth Annual Assessment of Barriers to Fair Access Within US Commercial Insurance Prescription Drug Coverage https://lnkd.in/gT8gEvRf
-
Maria Lowe, ICER's Associate Vice President of Pharmaceutical Intelligence, will be speaking at the iFHP | International Federation of Health Plans Oncology Tour in March 2025. Click here to learn more: https://lnkd.in/giruvQy4
The cost of cancer care is on the rise, yet new therapies—such as cell and gene therapies—continue to dramatically improve patient survival. How will payers balance this? iFHP’s second Future of Cancer Care Study Tour (24 - 28 March) investigates questions around clinical outcomes, cost-effectiveness, and the role of health insurance companies in creating a future where cancer care remains affordable, equitable, and easy to navigate for patients. See the range of speakers and our "welcome to 2025 offer" for iFHP members until end of January 2025. 👇 👏 https://shorturl.at/AnP1Y We have located the first three days of clinical learning UPMC Health Plan in Pittsburgh giving participants the opportunity to spend time within a leading US based payer and hospital group, plus meet UPMC Enterprises with their portfolio of investments in novel therapeutics and innovative treatments. There will be a day devoted to payment, pricing and contracting through Value Based Health Care models with Harold Miller and Maria Lowe from ICER. The week will end with members attending the Cancer Care at a Crossroads conference held at the New York Genome Center. Members attending our iFHP study tour are automatically registered to attend this conference on March 28
-
-
Institute for Clinical and Economic Review Publishes Final Evidence Report on Treatment for Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease: https://lnkd.in/gyXywS6j
Institute for Clinical and Economic Review Publishes Final Evidence Report on Treatment for Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease - ICER
https://icer.org
-
ICER #WeeklyView: ICER’s Unsupported Price Increase Report, acute pain Draft Evidence Report, & FDA’s latest on accelerated approval https://conta.cc/4iBzvNN
-
Institute for Clinical and Economic Review Announces Most Significant Drug-Price Hikes Unsupported by New Clinical Evidence in US: https://lnkd.in/gD3AjQeX
Institute for Clinical and Economic Review Announces Most Significant Drug-Price Hikes Unsupported by New Clinical Evidence in US - ICER
https://icer.org
-
ICER #WeeklyView: Upcoming ICER reports, employers on gene therapy pricing, and the acoramidis approval https://conta.cc/41lwX09
-
ICER #WeeklyView: A new topic announcement, more on anti-obesity meds, & PBMs sue FTC https://conta.cc/48YHOix
-
This past week, ICER’s Dan Ollendorf, PhD, MPH, attended and spoke on a panel at the ISPOR 2024 conference in Barcelona. Take a look at some highlights from the conference! #heor #hta #drugpricing #healthcare #health #ISPOREurope
-